About

Publications While At HealthPartners

selected publications

Journal Article

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 

Lancet Oncology. 2018

Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. 

New England Journal of Medicine. 2018

Contact

full name

J. Vansteenkiste

Quick Info

 

Collaboration

Co-author network

Map of science